| A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo H Kuruma, H Matsumoto, M Shiota, J Bishop, F Lamoureux, C Thomas, ... Molecular cancer therapeutics 12 (5), 567-576, 2013 | 124 | 2013 |
| A spontaneous developmental lineage plasticity that underlies the response of prostate cancer cells to androgen deprivation J Caradec*, A Lubik*, M Nouri, N Li, J Bishop, M Gleave, R Buttyan Cancer Research 74 (19_Supplement), 3017-3017, 2014 | | 2014 |
| Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy A Davies, C Bostock, M Ahmed, YY Lin, F Johnson, KM Nip, K Ketola, ... Cancer Research 78 (16_Supplement), A033-A033, 2018 | | 2018 |
| Abstract C25: Hsp27 is required for EGF-induced epithelial to mesenchymal transition in prostate cancer T Cordonnier, JL Bishop, M Shiota, A Takeuchi, KM Nip, M Gleave, ... Cancer Research 73 (3_Supplement), C25-C25, 2013 | | 2013 |
| Abstract C91: Targeting enzalutamide resistance in prostate cancer. K Ketola, J Bishop, M Gleave, A Zoubeidi Molecular Cancer Therapeutics 12 (11_Supplement), C91-C91, 2013 | | 2013 |
| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ... Nature cell biology 23 (9), 1023-1034, 2021 | 91 | 2021 |
| Anti-Salmonella Immunity: Highlighting Mucosal New Research in Vaccines, Immunology and Systemic Disease JL Bishop, ET Arena, KW Harder, B Brett Salmonella: From Genome to Function, 241, 2011 | | 2011 |
| Anti-Salmonella immunity: Highlighting new research in vaccines, mucosal immunology and systemic disease J Bishop, E Arena, K Harder, B Finlay Salmonella: From Genome to Function, Norfolk, UK, 241-274, 2011 | 1 | 2011 |
| Beyond immune checkpoint blockade: New approaches to targeting host–tumor interactions in prostate cancer: Report from the 2014 Coffey–Holden prostate cancer Academy meeting AK Miyahira, HT Kissick, JL Bishop, DY Takeda, CE Barbieri, JW Simons, ... The Prostate 75 (4), 337-347, 2015 | 15 | 2015 |
| Castration-Resistant Prostate Cancer AH Davies, JL Bishop, A Zoubeidi Precision Molecular Pathology of Prostate Cancer, 297-322, 2018 | 2 | 2018 |
| Characterizing the role of the inositol phosphatase SHIP-1 in the innate immune response to intracellular infection JL Bishop, L Sly, G Krystal, B Finlay JOURNAL OF LEUKOCYTE BIOLOGY, 57-57, 2005 | | 2005 |
| Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis N Al Nakouzi, CK Wang, E Beraldi, W Jager, S Ettinger, L Fazli, L Nappi, ... EMBO molecular medicine 8 (7), 761-778, 2016 | 36 | 2016 |
| Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho, K Yousefi, P Hurley, ... Prostate cancer and prostatic diseases 20 (1), 28-35, 2017 | 144 | 2017 |
| Deception point: peptidoglycan modification as a means of immune evasion JL Bishop, EC Boyle, BB Finlay Proceedings of the National Academy of Sciences 104 (3), 691-692, 2007 | 12 | 2007 |
| Efficient conditional reprogramming of differentiated prostate cancer cells back to a stem cell-like state with increased aggressive properties J Caradec, AA Lubik, M Nouri, N Li, M Altimarano-Dimas, J Bishop, ... Cancer Research 75 (15_Supplement), 4073-4073, 2015 | | 2015 |
| EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer A Davies, M Ahmed, C Bostock, A Gleave, K Ketola, F Johnson, J Bishop, ... Cancer Research 77 (13_Supplement), 5025-5025, 2017 | | 2017 |
| Friend or foe? Antimicrobial peptides trigger pathogen virulence JL Bishop, BB Finlay Trends in molecular medicine 12 (1), 3-6, 2006 | 40 | 2006 |
| Galiellalactone derivative targets stem cell population in ENZ-resistant prostate cancer through inhibition of STAT3 S Vahid, D Thaper, A Davies, MJ Van Rensburg, K Gibson, K Ketola, ... Cancer Research 76 (14_Supplement), 3342-3342, 2016 | | 2016 |
| Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer D Thaper, S Vahid, R Kaur, S Kumar, S Nouruzi, JL Bishop, M Johansson, ... Scientific reports 8 (1), 17307, 2018 | 34 | 2018 |
| Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer AW Wyatt, F Mo, K Wang, B McConeghy, S Brahmbhatt, L Jong, ... Genome biology 15, 1-14, 2014 | 92 | 2014 |
